| 000 | 01537 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250515220355.0 | ||
| 264 | 0 | _c20100817 | |
| 008 | 201008s 0 0 eng d | ||
| 022 | _a1573-904X | ||
| 024 | 7 |
_a10.1007/s11095-010-0113-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDominiak, Kristin | |
| 245 | 0 | 0 |
_aCritical need for clinical trials: an example of a pilot human intervention trial of a mixture of natural agents protecting lymphocytes against TNF-alpha induced activation of NF-kappaB. _h[electronic resource] |
| 260 |
_bPharmaceutical research _cJun 2010 |
||
| 300 |
_a1061-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aBiological Products _xpharmacology |
| 650 | 0 | 4 |
_aCatechin _xanalogs & derivatives |
| 650 | 0 | 4 |
_aCurcumin _xtherapeutic use |
| 650 | 0 | 4 |
_aDNA _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoflavones _xtherapeutic use |
| 650 | 0 | 4 |
_aLymphocytes _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNF-kappa B _ximmunology |
| 650 | 0 | 4 |
_aNeoplasms _xprevention & control |
| 650 | 0 | 4 |
_aOxidative Stress _xdrug effects |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _ximmunology |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aMcKinney, Jaclyn | |
| 700 | 1 | _aHeilbrun, Lance K | |
| 700 | 1 | _aSarkar, Fazlul H | |
| 773 | 0 |
_tPharmaceutical research _gvol. 27 _gno. 6 _gp. 1061-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s11095-010-0113-y _zAvailable from publisher's website |
| 999 |
_c19732711 _d19732711 |
||